On October 30, 2024, Alan Fuhrman, Chief Financial Officer of Tyra Biosciences Inc (TYRA, Financial), purchased 9,500 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 12,849 shares of Tyra Biosciences Inc.
Tyra Biosciences Inc is focused on developing precision medicine for patients with oncology indications. This approach targets specific genetic mutations within cancer cells to offer more effective and tailored treatment options.
The transaction occurred with shares priced at $16 each, valuing the purchase at $152,000. This acquisition has adjusted the insider's stake in the company significantly.
Over the past year, the insider transaction history at Tyra Biosciences Inc shows a trend with 1 insider buy and 14 insider sells. Alan Fuhrman's recent purchase marks a notable increase in insider ownership, contrasting with the broader selling trend.
The company's shares currently hold a market cap of approximately $865.49 million. Investors also monitor various valuation metrics such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow to gauge the stock's potential.
For further insights into the company's valuation, investors can refer to the GF Value, which provides an estimate of the intrinsic value of the stock based on historical multiples, adjusted for future business growth expectations.
This insider buying activity could be a signal to investors about the confidence level of management in the company's future prospects, especially in the context of the company's current valuation and stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
